FDA Approval Alert: The Need-to-Know | Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

In December 2022, the FDA has approved mosunetuzumab-axgb for patients with relapsed/refractory follicular lymphoma after 2 prior lines of therapy.

An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.
Examining Ongoing Studies of Mosunetuzumab for R/R Follicular Lymphoma and Addressing Accessibility
Video
Jan 19, 2023 1:00 PM
An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.
An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.
Mosunetuzumab Appears to Reduce Unmet Needs Associated With CAR T-Cell Therapy for R/R Follicular Lymphoma
Video
Jan 17, 2023 1:00 PM
An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.
An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.
Approval of Mosunetuzumab Becomes ‘Critically Important’ First-Line Treatment Option in R/R Follicular Lymphoma, Expert Says
Video
Jan 15, 2023 3:00 PM
An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.
FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma
FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma
Article
Dec 23, 2022 2:27 PM
The FDA’s decision to approve mosunetuzumab marks the first bispecific antibody approved to treat follicular lymphoma.